Fiocruz and MoH plan largest vaccine factory in LatAm

1 March 2021

Brazil’s Ministry of Health (MoH) and Fiocruz last week launched a public notice for the construction of the Industrial Complex of Biotechnology in Health (Cibs, in the Portuguese acronym).

The document opens a bidding process for hiring investors interested in participating in the construction of a new complex of the Immunobiological Technology Institute of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), in Santa Cruz, in Rio de Janeiro.

Bio-Manguinhos director/Fiocruz, Maurício Zuma, said he was thrilled with the event, remembering that the Institute has reached this moment after going a long way of studies, meetings, and a lot of dedication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK